Market capitalization | $208.29b |
Enterprise Value | $225.90b |
PER (TTM) P/E ratio | 14.35 |
EV/FCF (TTM) EV/FCF | 17.77 |
EV/Sales (TTM) EV/Sales | 4.64 |
P/S ratio (TTM) P/S ratio | 4.28 |
P/B ratio (TTM) P/B ratio | 5.48 |
Dividend yield | 3.51% |
Last dividend (FY24) | $3.74 |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
28 Analysts have issued a Novartis ADR forecast:
28 Analysts have issued a Novartis ADR forecast:
Mar '24 |
+/-
%
|
||
Turnover | 48,656 48,656 |
5%
5%
|
|
Gross income | 35,098 35,098 |
1%
1%
|
|
EBITDA | 21,168 21,168 |
4%
4%
|
EBIT (operating result) EBIT | 13,330 13,330 |
5%
5%
|
Net profit | 15,245 15,245 |
117%
117%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Head office | Switzerland |
CEO | Vasant Narasimhan |
Employees | 76,057 |
Founded | 1996 |
Website | www.novartis.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.